Patent
Anti-angiogenic compositions and methods of use
Reads0
Chats0
TLDR
In this article, an anti-angiogenic factor and a polymeric carrier were used for embolization of blood vessels and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.Abstract:
The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and paclitaxel. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.read more
Citations
More filters
Patent
Electrostatic abluminal coating of a stent crimped on a balloon catheter
TL;DR: In this paper, a method for electrostatic abluminal coating of a stent crimped on a balloon catheter is described, where a conductive wire is threaded through the lumen of the stent-balloon assembly and a charge is applied thereto.
Patent
Medical Device with Crystalline Drug Coating
TL;DR: In this paper, a medical device having a polymer-free outer surface layer comprising a crystalline drug selected from the group consisting of everolimus, tacrolimus, sirolimus and rapamycin is described.
Patent
Multiple imaging mode tissue marker
TL;DR: In this article, an intracorporeal marker for marking a site within living tissue of a host having a body of porous hydroxyapatite whose physical properties permit the body to be distinguished from human soft tissue under visualization using ultrasonic and radiation imaging modalities.
Patent
Implantable medical devices incorporating plasma polymerized film layers and charged amino acids
TL;DR: An implantable medical device, such as a stent, is disclosed comprising an amino acid or a polypeptide bonded to a plasma polymerized film layer formed on the device as discussed by the authors.
References
More filters
Journal ArticleDOI
The pathogenesis of atherosclerosis: a perspective for the 1990s
TL;DR: The ability to control the expression of genes encoding these molecules and to target specific cell types provides opportunities to develop new diagnostic and therapeutic agents to induce the regression of the lesions and, possibly, to prevent their formation.
Journal ArticleDOI
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis.
TL;DR: It is shown that vascular endothelial growth factor (VEGF) probably functions as a hypoxia-inducible angiogenic factor and is specifically induced in a subset of glioblastoma cells distinguished by their immediate proximity to necrotic foci and the clustering of capillaries alongside VEGF-producing cells.
Journal ArticleDOI
A Comparison of Balloon-Expandable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery Disease
Patrick W. Serruys,P. de Jaegere,Ferdinand Kiemeneij,Carlos Macaya,Wolfgang Rutsch,Gr. Heyndrickx,H. Emanuelsson,Jean Marco,Victor Legrand,P. Materne +9 more
TL;DR: The clinical and angiographic outcomes were better in patients who received a stent than in those who received standard coronary angioplasty, however, this benefit was achieved at the cost of a significantly higher risk of vascular complications at the access site and a longer hospital stay.
Journal ArticleDOI
A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease
David L. Fischman,Martin B. Leon,Donald S. Baim,Richard A. Schatz,Michael P. Savage,Ian M. Penn,Katherine D. Detre,Lisa Veltri,Donald R. Ricci,Masakiyo Nobuyoshi,Michael W. Cleman,Richard R. Heuser,David Almond,Paul S. Teirstein,R. David Fish,Antonio Colombo,Jeffrey C. Brinker,Jeffrey Moses,Alex Shaknovich,John N. Hirshfeld,Stephen Bailey,Stephen E. Ellis,Randal Rake,Sheldon Goldberg +23 more
TL;DR: In selected patients, placement of an intracoronary stent, as compared with balloon angioplasty, results in an improved rate of procedural success, a lower rate of angiographically detected restenosis, a similar rate of clinical events after six months, and a less frequent need for revascularization of the original coronary lesion.
Journal ArticleDOI
Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.
Donald R. Senger,Stephen J. Galli,Ann M. Dvorak,Carole A. Perruzzi,V. Susan Harvey,Harold F. Dvorak +5 more
TL;DR: Tumor ascites fluids from guinea pigs, hamsters, and mice contain activity that rapidly increases microvascular permeability, and this activity is secreted by these tumor cells and a variety of other tumor cell lines in vitro.